newsfilter
← Latest News
Business Wire·

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Major milestone achieved with successful completion of enrollment for LP-184 Phase 1a clinical trial, with 65 patients enrolled across a range of solid tumors including glioblastoma (GBM); LP-184 is a potential